Gastrin I (human) in Intestinal Organoid Research: Advancing Gastrointestinal Physiology Studies

Introduction

Gastrin I (human) is an endogenous regulatory peptide central to the modulation of gastric acid secretion and gastrointestinal physiology. As a potent CCK2 receptor agonist, its action on gastric parietal cells underpins many fundamental and pathological processes in the digestive tract. While traditional research has focused on in vivo and cell line models, recent breakthroughs in stem cell-derived intestinal organoids have provided unprecedented opportunities to model human gastrointestinal biology and disease. This article examines the strategic application of Gastrin I (human) in these advanced systems, emphasizing its utility in dissecting receptor-mediated signal transduction and proton pump activation, and drawing on new insights from the field of organoid-based pharmacokinetic research.

The Biological Function of Gastrin I (human) and Its Experimental Relevance

Gastrin I (human) is a 17-amino acid peptide (CAS: 10047-33-3, MW: 2098.22 Da), primarily synthesized in G-cells of the gastric antrum. Physiologically, it regulates gastric acid secretion by binding to the cholecystokinin B (CCK2) receptor on gastric parietal and enterochromaffin-like (ECL) cells. Upon activation, Gastrin I triggers a cascade of intracellular events, including phospholipase C activation, intracellular calcium mobilization, and subsequent stimulation of H⁺/K⁺-ATPase (proton pump), culminating in increased acid secretion. This makes the peptide a robust experimental tool for studies into the gastric acid secretion pathway and receptor-mediated signaling mechanisms relevant to both basic and translational gastrointestinal disorder research.

Human Intestinal Organoids: A New Frontier for Gastrointestinal Physiology and Drug Metabolism Studies

The advent of human pluripotent stem cell (hPSC)-derived intestinal organoids (IOs) has transformed the landscape of gastrointestinal research. Unlike conventional models (e.g., animal models or Caco-2 cell lines), IOs authentically recapitulate human small intestinal structure and function, including the presence of diverse epithelial cell types and relevant transporter and enzyme activity. As described by Saito et al. (European Journal of Cell Biology, 2025), hiPSC-derived IOs exhibit long-term self-renewal, differentiation into mature enterocytes, and functional expression of cytochrome P450 enzymes and transporters. These features position IOs as a gold standard for pharmacokinetic studies, intestinal barrier research, and investigation into the molecular underpinnings of gastrointestinal disorders.

Leveraging Gastrin I (human) in Organoid-Based Gastrointestinal Disorder Research

The integration of Gastrin I (human) into intestinal organoid systems offers unique advantages for probing mechanisms of proton pump activation and CCK2 receptor signaling within a physiologically relevant human context. In vitro, Gastrin I can be applied directly to IO-derived monolayers or 3D structures to model the effects of endogenous peptide signaling on acid secretion, epithelial differentiation, and downstream gene expression. This approach enables researchers to:

• Dissect the gastric acid secretion pathway in a human-derived system, facilitating translational insights.
• Study receptor-mediated signal transduction dynamics in health and disease, specifically via CCK2 receptor engagement.
• Evaluate the impact of genetic or pharmacological interventions on proton pump activation and acid secretion regulation.
• Model disease states such as hypergastrinemia, Zollinger-Ellison syndrome, or atrophic gastritis within organoid platforms.

Moreover, the ability to generate patient-specific IOs allows for personalized analysis of gastric acid secretion regulators, supporting precision medicine approaches in gastrointestinal disorder research.

Experimental Considerations: Solubility, Handling, and Assay Design

For optimal use in organoid-based assays, researchers should note key properties of Gastrin I (human):

• Solubility: Insoluble in water and ethanol; readily soluble in DMSO at concentrations ≥21 mg/mL. Prepare fresh solutions to maintain activity.
• Stability: Store lyophilized peptide desiccated at -20°C. Avoid long-term storage of solutions; use promptly after reconstitution.
• Quality: High purity (≥98%) is confirmed by HPLC and mass spectrometry, ensuring assay reproducibility and minimal off-target effects.

In organoid protocols, Gastrin I can be added to culture media to stimulate parietal cell-like differentiation or to assess acute responses such as acid secretion, calcium flux, or downstream gene expression. Dose-response studies and time-course analyses are recommended, particularly when modeling disease-relevant hypergastrinemic states or testing the efficacy of CCK2 receptor antagonists.

Gastrin I (human) as a Tool for Deciphering CCK2 Receptor Signaling in IOs

One of the most powerful applications of Gastrin I in IO research lies in its capacity as a selective CCK2 receptor agonist. By stimulating CCK2 receptors, Gastrin I induces robust signaling cascades that can be quantified via downstream phosphorylation events (e.g., ERK1/2, PKC), transcriptional induction of acid secretion-related genes, and morphological changes in the organoid epithelium. This enables:

• Direct assessment of CCK2 receptor expression and function in patient-derived IOs.
• Mapping of signaling networks involved in gastric acid secretion and their dysregulation in gastrointestinal disorders.
• Screening of novel small molecule modulators or biologics targeting the CCK2 receptor pathway.

Such studies are not only foundational for understanding gastrointestinal physiology but also crucial for preclinical drug discovery efforts targeting acid-related diseases.

Integration with Pharmacokinetic and Barrier Function Studies

The reference work by Saito et al. (2025) demonstrates that hiPSC-derived IOs accurately express drug-metabolizing enzymes and transporters, making them highly suitable for pharmacokinetic evaluations. Incorporating Gastrin I (human) into these models extends their utility by allowing:

• Investigation of how acid secretion regulators modulate intestinal epithelial barrier properties.
• Analysis of drug absorption and metabolism under conditions of altered acid secretion, mimicking in vivo gastric environments.
• Modeling of co-morbid gastric and intestinal pathologies within the same experimental framework.

This dual approach offers a comprehensive platform for gastrointestinal physiology studies, linking peptide hormone signaling to drug disposition and epithelial function.

Practical Guidance for Advancing Organoid-Based Gastric Acid Secretion Pathway Research

When deploying Gastrin I (human) in IO systems, several best practices should be observed:

• Use freshly prepared, DMSO-dissolved peptide for each experiment to ensure maximal bioactivity.
• Employ appropriate controls, including CCK2 receptor antagonists and vehicle treatments, to validate specificity.
• Leverage quantitative readouts such as pH-sensitive dye assays, calcium imaging, or RT-qPCR to monitor functional responses.
• Consider co-culture or microfluidic approaches to more accurately recapitulate in vivo paracrine and autocrine signaling dynamics.

These strategies can refine the resolution and translational relevance of gastric acid secretion pathway research, especially in disease modeling and preclinical drug screening.

Conclusion

The use of Gastrin I (human) as a gastric acid secretion regulator in advanced intestinal organoid systems represents a significant methodological advance in gastrointestinal physiology and disorder research. By enabling the precise dissection of CCK2 receptor signaling and proton pump activation within human-derived tissues, researchers can bridge the gap between in vitro experimentation and in vivo human biology. This approach complements and extends findings from traditional models, supporting the development of targeted therapies and personalized medicine strategies for acid-related and functional gastrointestinal disorders.

How This Article Differs from Previous Literature

Unlike earlier reviews such as Gastrin I (human): A Versatile Tool for Gastric Acid Secr..., which focused primarily on the peptide's utility in classical in vitro and animal models, this article provides novel insights into the application of Gastrin I (human) within state-of-the-art human intestinal organoid systems. By integrating recent advances in organoid technology and referencing the pioneering work of Saito et al. (2025), this piece offers practical guidance for leveraging Gastrin I in translational research settings, emphasizing its value in pharmacokinetic studies, disease modeling, and precision medicine. This expanded perspective enables investigators to adopt cutting-edge methodologies that more closely approximate human gastrointestinal physiology and pathophysiology.